Etanercept: A tumor necrosis factor inhibitor for psoriasis and psoriatic arthritis

Expert Review of Dermatology

Volumn 1, Issue 4, 2006, Pages 527-534

  Gratch, Noah ^a   Weinberg, Jeffrey M ^b   Alexis, Andrew F ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

cytokine; etanercept; psoriasis; rheumatoid arthritis; tumor necrosis factor

Indexed keywords

EID: 34250312610     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.4.527     Document Type: Article

References (59)

1. Freedberg IM, Eisen AZ, Wolff K et al. Dermatology in General Medicine. McGraw-Hill, 44 (1999).
2. Bonifati C, Ameglio F. Cytokines in psoriasis. Int. J. Dermatol. 38, 241–251 (1999).
3. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol. Clin. 22, 449–459 (2004).
4. Ettehadi P, Greaves WM, Wallach D, Aderka D, Camp RDR. Elevated tumor necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96, 146–151 (1994).
5. Bonifati C, Carducci M, Cordial Fei P et al. Correlated increases of tumor necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease activity. Clin. Exp. Dermatol. 19, 383–387 (1994).
6. Mussi A, Bonifati C, Carducci M et al. Serum TNF-α levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J. Biol. Regul. Homeost. Agents 11, 115–118 (1997).
7. Partsch G, Steiner G, Leeb BF, Dunky F, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. 2, 518–523 (1997).
8. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356, 385–390 (2000).
9. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis. Arthritis Rheum. 50, 2264–2272 (2004).
10. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. 42, 829–830 (2000).
11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357, 1842–1847 (2001).
12. Gottleib AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139, 1627–1632 (2003).
13. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014–2022 (2003).
14. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152, 1304–1312 (2005).
15. Enbrel, package insert. Amgen, CA, USA (2004).
16. Sacher C, Rubbert A, König C, Scharffetter-Kochanek K, Kreig T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept. J. Am. Acad. Dermatol. 46, 113–115 (2002).
17. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor α antagonist etanercept. Cutis 74, 245–247 (2004).
18. Lin M, Hsu C, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch. Dermatol. 141, 680–682 (2005).
19. Henter JI, Karlen J, Calming U, Bernstrand, Andersson U, Fadeel B. Successful treatment of Langerhans’-cell histiocytosis with etanercept. N. Engl. J. Med. 345, 1577–1578 (2001).
20. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor α-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 46, 1965–1968 (2002).
21. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 48, 2645–2651 (2003).
22. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-syndrome by TNF-α blockade. Immunobiology 206, 496–501 (2002).
23. Cortis E, De Benedetti F, Insalaco A et al. Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome. J. Pediatr. 145, 851–855 (2004).
24. Kovach BT, Calamia KT, Walsh JS, Ginsburg WW. Treatment of multicentric reticulohistiocytosis with etanercept. Arch. Dermatol. 140, 919–921 (2004).
25. Pasternack FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. Arch. Dermatol. 141, 13–15 (2005).
26. Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion protein. Br. J. Dermatol. 144, 597–600 (2001).
27. Robinson ND, Guitart J. Recalcitrant, recurrent apthous stomatitis treated with etanercept. Arch. Dermatol. 139, 1259–1262 (2003).
28. McGowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J. Drugs Dermatol. 3, 441–444 (2004).
29. Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. Regression of subacute lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor α-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum. 46, 1408–1409 (2002).
30. Sfikakis PP. Behçet’s disease: a new target for anti-tumor necrosis factor treatment. Ann. Rheum. Dis. 61 (Suppl. II), ii51 –ii53 (2002).
31. Melikoglu M, Fresko I, Mat C et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J. Rheumatol. 32, 98–105 (2005).
32. Stambe C, Wicks IP. TNF-α and response of treatment-resistant adult-onset Still’s disease to thalidomide. Lancet 352, 544–545 (1998).
33. Husni ME, Maier AL, Mease PJ et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 46, 1171–1176 (2002).
34. Fautrel B, Sibilia J, Mariette X, Combe B. Tumor necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann. Rheum. Dis. 64, 262–266 (2005).
35. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J. Am. Acad. Dermatol. 51, 200–204 (2004).
36. Utz JP, Limper AH, Kalra S et al. Etanercept for the treatment of stage II and stage III progressive pulmonary sarcoidosis. Chest 124, 177–185 (2003).
37. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J. Rheumatol. 30, 1864–1867 (2003).
38. Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: a pilot study. Arthritis Rheum. 43, S392 (2000) (Abstract).
39. Penas PF, Fernandez-Herrera J, Garcia-Diez A. Dermatologic treatment of cutaneous graft versus host disease. Am. J. Clin. Dermatol. 5, 403–416 (2004).
40. Hattori K, Hirano T, Miyajima H et al. Differential effects of anti-fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host-disease pathologies. Blood 91, 4051–4055 (1998).
41. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complimentary treatment for chronic graft-versus-host disease. Transplantation 73, 665–667 (2002).
42. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalized pustular psoriasis induced by cyclosporine a withdrawal responding to the tumor necrosis factor α inhibitor etanercept. Dermatology 205, 213–216 (2002).
43. Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis 72, 396–398 (2003).
44. Lebwohl M. New developments in the treatment of psoriasis. Arch. Dermatol. 138, 686–688 (2002).
45. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098–1104 (2001).
46. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum. Dis. Clin. North Am. 29, 185–202 (2003).
47. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis. 3, 148–155 (2003).
48. Hamilton CD. Infectious complications of treatment with biologic agents. Curr. Opin. Rheumatol. 16, 393–398 (2004).
49. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46, 3151–3158 (2002).
50. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 50, 1740–1751 (2004).
51. Adams AE, Zwicker J, Curiel C et al. Aggressive cutaneous T-cell lymphomas after TNFα blockade. J. Am. Acad. Dermatol. 51, 660–662 (2004).
52. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. 44, 2862–2869 (2001).
53. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138, 807–811 (2003).
54. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-α-induced systemic lupus syndrome. Clin. Rheumatol. 22, 56–61 (2003).
55. Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr. Opin. Rheumatol. 12, 49–52 (2000).
56. Maini R, St Clair EW, Breedveld et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932–1939 (1999).
57. Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117, 761–769 (1999).
58. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359, 579–580 (2002).
59. Enbrel patient information www.enbrel.com